Evidence map›Paper›PMID 32913149›Full record

ArticleEndoscopic ultrasound

Macroscopic on-site evaluation of biopsy specimens for accurate pathological diagnosis during EUS-guided fine needle biopsy using 22-G Franseen needle.

Junichi Kaneko, Hirotoshi Ishiwatari, Keiko Sasaki, Tatsunori Satoh, Junya Sato, Hiroyuki Matsubayashi, Yohei Yabuuchi, Yoshihiro Kishida, Masao Yoshida, Sayo Ito and 6 more

Open access · greenAbstract read
In one paragraph

Article in Endoscopic ultrasound. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Percutaneous Biopsy and Drainage of the Pancreas.Seminars in interventional radiology · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Junichi KanekoDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Hirotoshi IshiwatariDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Keiko SasakiDivision of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Tatsunori SatohDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Junya SatoDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroyuki MatsubayashiDivision of Endoscopy; Division of Genetic Medicine Promotion, Shizuoka Cancer Center, Shizuoka, Japan.
Yohei YabuuchiDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Yoshihiro KishidaDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Masao YoshidaDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Sayo ItoDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Noboru KawataDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kenichiro ImaiDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Naomi KakushimaDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kohei TakizawaDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Kinichi HottaDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroyuki OnoDivision of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
Weatherford College · USShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesMeasuring a visible core length during macroscopic on-site evaluation (MOSE) can be useful for accurate diagnoses during an EUS-guided fine needle biopsy (EUS-FNB). We aimed to estimate visible core cutoff lengths predictive of a correct diagnosis when using 22-gauge Franseen needles for biopsies from pancreatic masses. MATERIALS AND

methodsWe assessed 77 consecutive patients who underwent EUS-FNB using 22-gauge Franseen needles for pancreatic masses between March 2018 and October 2018. At least two needle passes were performed in all patients, irrespective of the findings on MOSE. The endoscopists measured the visible cores using a ruler during MOSE. The first two passes were analyzed on a per pass basis, and the correlation between visible core lengths and diagnostic accuracy was evaluated.

resultsWe evaluated 150 needle passes of 75 patients. The accuracy per pass was 92% (138/150). The median length of the visible cores was 15 (range: 0-60) mm and they were significantly longer in the correct diagnosis group than in the incorrect diagnosis group. The accuracy correlated positively with the visible core length. Receiver-operating characteristic curve analysis of the visible core length for accuracy demonstrated an optimal cutoff value of 10 mm. On multivariate logistic regression, visible core lengths >10 mm independently affected the correct diagnosis (odds ratio: 5.1, P= 0.02).

conclusionsVisible cores exceeding 10 mm may be useful for correct diagnosis while using a 22-gauge Franseen needle for EUS-FNB from pancreatic masses.

Indexed as

EUSEUS-FNAfine-needle biopsyFranseen needlemacroscopic on-site evaluation

Identifiers

PMID32913149
PMCPMC7811705
OpenAlexW3084243820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.